Purpose: The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective
inhibitor that has received regulatory approval for the treatment of patients with EGFR …

Molecular testing identifies patients with advanced non-small cell lung cancer (NSCLC) who
may benefit from targeted therapy or immunotherapy (ie, immune checkpoint inhibitor …

Simple Summary Non-small cell lung cancer treatment has undergone a revolution in the
past decade owing to the discovery of mutations that drive carcinogenesis and the …

The objective of this systematic review was to analyze the current state of the art of imaging-
derived biomarkers predictive of genetic alterations and immunotherapy targets in lung …

Simple Summary Liquid biopsy has recently been introduced as a novel method in cancer
diagnostics. It is less invasive for patients than conventional tissue biopsies, as the assay …

Introduction: Cancer immunotherapy has revolutionized the treatment of patients with
advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient …

Lung cancer is one of the main causes of cancer-related death worldwide. Despite
advances in lung cancer pathophysiology, diagnosis and prognosis, a better understanding …

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current
knowledge of cancer science and clinical oncology practice. This all-new edition is the …

Objectives To describe the treatment patterns and determine the effectiveness and safety of
nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan …

Background Human epidermal growth factor receptor (EGFR) is an oncogenic gene and one
of top targets of precision therapy in lung cancer with EGFR mutations. Although there are …